Skip to main content

Profile hero

Adam Golden

Partner and Head of US Life Sciences Transactions

Adam is a strong lawyer and a solid tactician on transactions.

Chambers USA 2022

Profile details

About Adam Golden

Adam heads US life sciences transactions. Based in New York, he advises clients on M&A, licenses and collaborations, venture capital financings and commercial transactions in the life sciences sector. A dual M&A and IP transactions lawyer, Adam has deep experience representing pharmaceutical, biotech and medical device companies and investors on a broad range of transactions, including hybrid deals such as M&A transactions with back-end milestone payments, carve-outs, options to acquire or license and product divestitures. He also regularly advises clients on related transition service, manufacturing and supply, and other operational agreements.

Adam is recognized as a leading life sciences practitioner by Chambers Global, Chambers USA, Legal 500 US, Who's Who Legal, LMG Life Sciences, IFLR1000 and IAM Patent 1000. He has been shortlisted as M&A Attorney of the Year and Life Sciences Star by LMG Life Sciences, and a Life Sciences MVP by Law360.

 

 

 

Recent work

Select M&A Transactions

  • Rayner Surgical on its acquisition of the product OMIDRIA® from Omeros Corporation in a transaction valued in excess of $1 billion.
  • Ipsen on the sale to Fusion Pharmaceuticals of rights to a radiopharmaceutical developed for oncology indications.
  • Novartis on its acquisition of Cadent Therapeutics, a clinical-stage neuroscience company.
  • Engrail Therapeutics on its acquisition of NeuroCycle Therapeutics, a company focused on sub-type selective GABA-A modulation.
  • Novartis on its acquisition of Vedere Bio, including a platform for AAV-based delivery of gene therapies and an optogenetics program.
  • Altavant Sciences on its acquisition of Onspira Therapeutics, a private drug development company focused on therapeutics for rare pulmonary diseases.
  • Bausch Health on its option to purchase the ophthalmology assets of Allegro Pharmaceuticals.
  • Novartis on its acquisition of IFM Tre for up to $1.6bn and its option to acquire IFM Due for up to $840m.
  • Celgene on its $9bn acquisition of Juno Therapeutics, a clinical-stage cell immunotherapy company.
  • Novartis on its $8.7bn acquisition of AveXis, a clinical-stage gene therapy biotech company.
  • Celgene on its acquisition of Impact Biomedicines for up to $7bn, a clinical stage company developing fedratinib for myelofibrosis.
  • Chase Pharmaceuticals on its sale to Allergan for up to $1bn.
  • Alcon Laboratories on its acquisitions of Encore Vision, RxSight and Transcend Medical.
  • Bausch Health on the sale of Dendreon Pharmaceuticals to Sanpower.

Select License and Collaboration Transactions

  • Novartis on its global co-development and co-commercialization agreement with UCB for Parkinson’s Disease therapies.
  • Spark Therapeutics on its collaboration and option agreement with Senti Biosciences with respect to the development of next-generation precision gene therapies.
  • Novartis on its exclusive worldwide license and collaboration agreement with Mesoblast Limited to develop remestemcel-L for the treatment of acute respiratory distress syndrome, including that associated with COVID-19.
  • Gilead Sciences on a license agreement with Xencor for the use of XmAB® antibody technologies in investigational agents for HIV.
  • Gilead Sciences on its strategic collaboration with Tango Therapeutics to develop and commercialize innovative targeted immuno-oncology treatments for cancer.
  • Kite, a Gilead company, on an up to $3bn deal to access Sangamo Therapeutics’ zinc finger nuclease technology.
  • Celgene on strategic collaborations with Kyn Therapeutics, Ex Scientia, Obsidian Therapeutics, Jounce Therapeutics and Skyhawk Therapeutics.
  • Gilead Sciences on its $150m collaboration with Agenus to develop and commercialize novel immuno-oncology therapies.
  • Novartis on its collaboration with Cellular Biomedicine Group to support the introduction of the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China.
  • Novartis on strategic collaborations with Sangamo Therapeutics, Surface Therapeutics, Xencor and Homology Medicines.

Qualifications

Education

New York University School of Law

  • J.D.

Princeton University

  • A.B.

Bar admissions

  • New York
  • Massachusetts